Asia Fresh News

Asia Fresh Stories

Archive for January 12th, 2016

Sunway’s New 4-Star Hotel Opens on 15 February 2016

leave a comment »


KUALA LUMPUR, Malaysia /PRNewswire/ — Sunway Hotels & Resorts is pleased to announce immediate booking availability for its newest 4-star hotel, Sunway Pyramid Hotel West, scheduled to open on Monday, 15 February 2016. Conveniently located on the west side of the iconic Sunway Pyramid Shopping Mall, the new 401-room Sunway Pyramid Hotel West is now accepting bookings at, via phone at +603-7492-8000 or by email directly to

Sunway Pyramid Hotel West (the tower on the left) complements the existing cluster of hotels within Sunway Resort City
Sunway Pyramid Hotel West (the tower on the left) complements the existing cluster of hotels within Sunway Resort City
401 Superior and Superior Executive rooms at the new 4-star Sunway Pyramid Hotel West
401 Superior and Superior Executive rooms at the new 4-star Sunway Pyramid Hotel West

Sunway Pyramid Hotel West’s introductory rates start from RM308.00++ per room per night, inclusive of breakfast for two (2) adults and are valid for stays from 15 February to 30 April 2016. Room rates are quoted in Ringgit Malaysia (RM) and are subjected to 10% Service Charge and prevailing Goods & Services Tax (GST).

The new 26-storey hotel features 401 Superior and Superior Executive rooms; with an option of providing unobstructed views of Sunway Lagoon theme park. Other facilities in Sunway Pyramid Hotel West include a restaurant, five (5) meeting rooms with a capacity of 20 to 150 persons, a gym and a swimming pool. Guests will also have access to facilities and are extended cross-signing privileges for outlets and services managed by Sunway Resort Hotel & Spa.

The opening of Sunway Pyramid Hotel West complements the existing cluster of hotels within Sunway Resort City, namely the 5-star 468-room flagship Sunway Resort Hotel & Spa and the 4-star 549-room Sunway Pyramid Hotel East. Guests have extensive business and leisure facilities to take advantage of within the 800-acres integrated resort development offering a choice of over 1,400 guestrooms, suites, duplexes and pool villas at Sunway Resort Hotel & Spa, Sunway Pyramid Hotel East and now Sunway Pyramid Hotel West, affording guests every conceivable budget and experience.

Enjoy the introductory room rates at Sunway Pyramid Hotel West by calling +603-7492-8000, Toll-free (Malaysia Only) 1-800-82-8888, email to or visit

FOR MEDIA ENQUIRIES, PLEASE CONTACT: Farizal B. Jaafar, Group Director of Brand Marketing & Communications – Sunway Hotels & Resorts or Stephanie Yong, Publicity & Media Relations Manager at Tel: +603-7492-8000 or E-mail:

Photo –
Photo –

Source: Sunway Resort Hotel & Spa

Written by asiafreshnews

January 12, 2016 at 6:03 pm

Posted in Uncategorized

KISCO Ltd. Announces Acquisition of Specialty Coating Systems, Inc.

leave a comment »

INDIANAPOLIS /PRNewswire/ — Today, KISCO Ltd., an international supplier of high-quality materials, products and services, has announced its acquisition of Specialty Coating Systems, Inc., a global leader in Parylene coating services and technologies. Both well-recognized brands, KISCO has been operating in the Parylene market for over 18 years with a strong background in materials science and development, and SCS has notable roots back to the origination of Parylene and has been a leading contributor in the expansion of the worldwide Parylene market.

Logo –

Over the coming year, the merged Parylene organization will begin to operate globally as Specialty Coating Systems, a KISCO company, and will build upon the legacies and strengths that the companies have built over their cumulative 63 years of Parylene experience. The acquisition represents a significant milestone in the industry as it further positions the company as the industry leader with enhanced manufacturing capabilities around the world and unmatched research, development and applications experience.

President of KISCO Ltd. Takekazu Kishimoto said of the announcement, “We are pleased to welcome Specialty Coating Systems into the KISCO family. The management teams at KISCO and SCS are committed to continuing our strong leadership positions in the industry by providing high quality Parylene services and technologies to our customers through a combined 21 regionally positioned facilities throughout the Americas, Europe and Asia. We are also committed to expanding the market by developing and commercializing new, cutting-edge materials, processes and technologies, which will be made possible by the consolidation of our highly successful engineering teams.”

Terry Bush, SCS President & CEO, added, “This is an exciting time for our company and customers. I am proud of what Specialty Coating Systems has accomplished in the market throughout our company’s long history and am confident that the consolidation of our two companies will create an even stronger entity to better serve our customers in the future. SCS and KISCO remain committed to the highest level of quality products and customer service experiences, and we are excited about the opportunity to offer customers additional resources, locations and coating options to help make their innovations successful.”

For more information about Parylene conformal coatings and these companies, visit

About KISCO Ltd.
Since 1921, KISCO has been at the forefront of materials science and polymer materials, providing customers with innovative solutions throughout five divisions, including synthetic resins, chemical products, electronics materials, packaging materials, and diX Parylene coatings. Headquartered in Osaka, Japan, KISCO operates trading companies, development, production and processing facilities around the world. For more information on KISCO Ltd., please visit

About Specialty Coating Systems
Headquartered in Indianapolis, IN, SCS is the worldwide leader in Parylene conformal coating services and technologies.  As the direct descendant of the companies that originally developed Parylene, SCS has 45 years of experience and expertise that it leverages for its customers through coating facilities throughout the Americas,Europe and Asia. The company also offers industry-leading liquid coating systems including spray, spin and dip coating systems and ionic contamination test systems.  For more information on SCS, please

Source: Specialty Coating Systems

Written by asiafreshnews

January 12, 2016 at 6:01 pm

Posted in Uncategorized

Subang Jaya Medical Centre (“SJMC”) and BookDoc Sign an MoU to Improve Medical Care via Mobile Technology

leave a comment »

KUALAR LUMPER, Malaysia /PRNewswire/ — Subang Jaya Medical Centre (SJMC), a leading tertiary healthcare provider, and BookDoc, an online healthcare app, signed a memorandum of understanding (MoU) today in an effort to simplify the process of making doctors’ appointments. The MoU was signed by Elaine Cheong, Country CEO of Ramsay Sime Darby Health Care (RSDH) and Datuk Chevy Beh, founder of BookDoc.

Ramsay Sime Darby Health Care Director of Branding & Communications, Edgar Toral (on the left) with BookDoc Founder, Dato Chevy Beh (on the right)
Ramsay Sime Darby Health Care Director of Branding & Communications, Edgar Toral (on the left) with BookDoc Founder, Dato Chevy Beh (on the right)

Via the newly launched app, patients, from both Malaysia and abroad, can easily browse through the extensive list of specialists at SJMC and make appointments with the doctors who best meet their requirements.

Through this collaboration, SJMC and BookDoc hope to work hand in hand to enhance and improve the outcomes for healthcare services in the region, and thanks to innovations like BookDoc, patients and doctors can now be connected at all times.

Both parties will also benefit greatly from this partnership. SJMC will gain access to BookDoc’s expanding network of patients from across the region and BookDoc will benefit from working with one of the most reputable names in the Malaysian healthcare industry.

With over 30 years of medical excellence, SJMC is the flagship hospital under Ramsay Sime Darby Health Care and is a top name in the Malaysian medical scene with various clinical and surgical milestones in adult cardiac surgery, paediatric liver transplant, cancer therapies and interventional radiology. The multiple award-winning hospital also boasts Centres of Excellence for Cancer, Blood Diseases, and Digestive and Liver Health.

“RSDH is constantly keeping up with the times and this is evidenced through our state-of-the-art equipment and various innovations that improve patient outcomes. We take pride in being an innovative healthcare provider as we want to meet the ever-changing needs of our community”, said Elaine Cheong.

“This collaboration is very timely as it is in line with our aspiration to extend our multidisciplinary specialist care services locally and internationally. With BookDoc, SJMC’s specialist doctors, whose expertise range General Internal Medicine to Neurology and Nuclear Medicine, become more accessible to patients via their availability time slots. In addition, BookDoc will help minimise the waiting time for the patients while optimising the work schedule of its specialist doctors”.

According to Cheong, this collaboration will serve as a starting point for future projects, which may include real-time appointment bookings with RSDH’s specialist doctors and online purchases of health screening packages.

“RSDH operates three major multi-disciplinary hospitals and we aim to deliver the best clinical outcomes to patients through our highly skilled experts, cutting-edge technological equipment and excellent patient care. Over the last three decades, we have built a sterling reputation as an internationally recognised brand with numerous achievements and milestones,” she added.

“I am excited to see how BookDoc can potentially change the way the public access healthcare services”, saidDatuk Chevy Beh. “I hope that through this innovation, the waiting time to see doctors will be reduced significantly and that sometime in the near future, BookDoc will be able to provide the public with information on the nearest healthcare service within minutes when an emergency arises,” he added.

Ramsay Sime Darby Health Care Director of Branding & Communications, Edgar Toral said that digital and mobile platforms make it easier for patients to source for credible medical information related to symptoms and treatments as well as facilitate the booking of appointments with trusted doctors and medical facilities.

“We believe that with BookDoc, the Ramsay Sime Darby Health Care group of hospitals in Malaysia will improve patients’ accessibility to our network of hospitals and medical professionals,” he added.

About Ramsay Sime Darby Health Care

Ramsay Sime Darby Health Care (RSDHC) is equally owned by Sime Darby Berhad and Ramsay Health Care Limited. With a workforce of over 100,000 employees in over 20 countries, Sime Darby is a Malaysia based diversified multinational involved in key growth sectors namely, plantation, property, motors, industrial equipment, energy & utilities and healthcare. Ramsay Health Care is the largest private hospital group in Australia and a growing global healthcare group with hospitals in France, the United Kingdom, Indonesia and Malaysia with over 250 hospitals across five countries.

This joint venture company, Ramsay Sime Darby Health Care combines Sime Darby’s healthcare portfolio assets in Malaysia namely Subang Jaya Medical Centre, Ara Damansara Medical Centre, ParkCity Medical Centre, Mediplex and Ramsay Sime Darby Healthcare College, with Ramsay Health Care’s three hospitals in Indonesianamely RS Premier Jatinegara, RS Premier Bintaro and RS Premier Surabaya.

About Subang Jaya Medical Centre 

Subang Jaya Medical Centre (SJMC) is a 393-bed multi-disciplinary tertiary hospital nestled in the heart of Subang Jaya. This one-stop medical centre has delivered medical excellence with state-of-the-art systems and cutting edge technology to the community since it opened its doors in 1985. This award-winning tertiary care hospital has 14 operating theatres and 93 clinic suites. SJMC physicians treat approximately 1,800 outpatients and 300 inpatients each day and the majority of the hospital’s 190 specialists, many of whom are key opinion leaders in their respective fields in the region, were trained in the UK, US or Australia. Offering all major specialties, the hospital management and staff pride themselves on the use of revolutionary medical technologies and their international reputation for clinical excellence. The hospital’s Cancer & Radiosurgery Centre (CRC) has positioned itself at the forefront of cancer treatment facilities in this country since its launch in 2001.

About BookDoc

BookDoc is a Malaysian online healthcare platform that connects and unites patients and healthcare professionals, bringing forth timely access, resource optimisation and informed choices. The app links those in need with those who can assist them at anytime and anywhere, in which precious time is optimised for all parties, and the benefits of early access to care realised. BookDoc, backed by a diverse group investors from entrepreneurs to seasoned healthcare and insurance professionals, banker, regulators as well as ICT professionals, had made record achieving the highest pre-seed and seed valuation in Asia tech app history.


Name: Ms. Valerie Voon
Tel: +6019-336 6758

Name: Mr. Edgar Toral
Tel: +603-7839 9907

Photo –

Ramsay Sime Darby Health Care

Written by asiafreshnews

January 12, 2016 at 6:00 pm

Posted in Uncategorized

Renault-Nissan to Launch More Than 10 Vehicles with Autonomous Drive Technology over the Next Four Years

leave a comment »

SUNNYVALE, Calif. /PRNewswire/ —

  • World’s fourth largest car group confirms autonomous drive and connectivity timeline through 2020
  • Fatal and serious injuries have been significantly reduced; new technologies will help make cars even safer
  • Car group hires new executive to oversee connectivity and connected car services globally

The Renault-Nissan Alliance will launch more than 10 vehicles with autonomous drive technology in the next four years.

(Logo: )

The global car group confirmed today that it will launch a range of vehicles with autonomous capabilities in the United States, Europe, Japan and China through 2020. The technology will be installed on mainstream, mass-market cars at affordable prices.

In addition, Renault-Nissan will launch a suite of new connectivity applications that will make it easier for people to stay connected to work, entertainment and social networks.

“Renault-Nissan Alliance is deeply committed to the twin goals of ‘zero emissions and zero fatalities,'” Renault-Nissan Alliance Chairman and CEO Carlos Ghosn said at the Renault-Nissan Silicon Valley Research Center. “That’s why we are developing autonomous driving and connectivity for mass-market, mainstream vehicles on three continents.”

Zero emission and zero fatalities

Renault-Nissan is already the industry’s zero-emission leader by far. The Alliance has sold nearly 300,000 all-electric vehicles since the first Nissan LEAF was sold in the San Francisco Bay Area in December 2010.

Safety and efficiency of vehicles across the Renault-Nissan Alliance have increased dramatically. For instance, fatal and serious injuries in Nissan vehicles in Japan decreased 61 percent in 20 years; fatal and serious injuries in Renault vehicles in France decreased 80 percent in 15 years.

Autonomous drive is expected to help further reduce driver error, which is responsible for up to 90 percent of all fatalities.

2016 will mark the debut of vehicles with “single-lane control,” a feature that allows cars to drive autonomously on highways, including in heavy, stop-and-go traffic. In 2018, Renault-Nissan will launch vehicles with “multiple-lane control,” which can autonomously negotiate hazards and change lanes during highway driving. And 2020 will see the launch of “intersection autonomy,” which can navigate city intersections and heavy urban traffic without driver intervention.

For the full press release as well as related photos and video, go to:

Aline Henry
Renault-Nissan Alliance Communications

Source: Renault-Nissan Alliance

Written by asiafreshnews

January 12, 2016 at 5:48 pm

Posted in Uncategorized

Sequa Petroleum N.V. General Meeting Results 7th January 2016

leave a comment »

LONDON /PRNewswire/ — The Company confirms that at its General Meeting held on 7 January inAmsterdam, all resolutions were passed by attending shareholders representing 71.52 % of the issued share capital of the Company.


Jacob Broekhuijsen – CEO
Carol Frost – Director HR & Communication
+44(0)203-728-4450 or

Source: Sequa Petroleum N.V.

Written by asiafreshnews

January 12, 2016 at 5:25 pm

Posted in Uncategorized

Finesse Solutions Launches TruBio DV 5.0 Bioreactor Control Software with new User Interface and DeltaV Batch S88 capability

leave a comment »

SANTA CLARA, Calif. /PRNewswire/ — Finesse Solutions, Inc., Santa Clara, CA, a manufacturer of measurement and control solutions for life science process applications, announced the release of TruBio® DV version 5.0 control software for both bioreactors and mixers.  TruBio 5.0 enhances control by more fully leveraging Finesse SmartParts™ components.  TruBio DV software can be used with glass vessels, rockers, media or buffer mixers, and most sizes/brands of single-use bioreactors to provide a seamless solution from 0.5L R&D through 2000L cGMP-compliant production.

TruBio DV version 5.0 continues to be powered by a DeltaV® Controller from Emerson Process Management and is optimized for DeltaV versions 12 and 13. It is also compatible with the Emerson DeltaV batch platform for cGMP-compliant operation and Syncade-based MES systems.

TruBio DV 5.0 has been enhanced to utilize Finesse’s new SmartParts family of intelligent digital actuators to implement off-the-shelf solutions for continuous processing and automated harvest.  In addition, the software can be used to create batch recipes for media mixing and/or buffer preparation.  TruBio DV 5.0 retains the full capabilities of the “multi-feed” dosing function to deliver low volume feed additive doses with high precision and allows scalability to large doses into production systems. With its graphical interface improved for consistency, ease of visualization and enhanced alarming, TruBio DV 5.0 fully supports Finesse Universal Controllers to create a unique and flexible upstream bio-processing solution.

About Finesse Solutions, Inc.

California-based Finesse Solutions, Inc., has established a proven record in providing turn-key, scalable solutions for single-use upstream bio-processing.  The Finesse product platform includes novel disposable sensors, modular automation hardware, and intelligent software that can harmonize data and technology transfer globally.   Finesse also offers a complete set of services including commissioning and validation for rapid and reliable deployment of single-use equipment. For more information, please visit us at

Source: Finesse Solutions, Inc.
Related Links:

Written by asiafreshnews

January 12, 2016 at 5:15 pm

Posted in Uncategorized

APR Energy Shareholders Approve Consortium Acquisition, Privatization

leave a comment »

JACKSONVILLE, Florida /PRNewswire/ — APR Energy plc (the “Company”) (LSE: APR), a global leader in fast-track power solutions, announces today that an offer by a consortium of investors (the “Consortium”) to acquire the Company was declared unconditionally successful on 5 January. The Consortium comprises Fairfax Financial Holdings Limited, ACON Equity Management and Albright Capital Management, and brings substantial financial backing to support the Company’s business initiatives, including committing more than $200 million in fresh equity capital to reduce debt and increase working capital.

Logo –

“This is a significant milestone in the evolution of APR Energy,” said Executive Chairman John Campion. “We are pleased to be working alongside a group that truly understands our business and our market – and that shares our longer-term vision. Our new investors bring significant strategic value to our business, including global relationships, a sophisticated understanding of international finance and extensive experience investing in global power markets. Their significant investment reflects a strong belief in our business, our market and our management team, and we expect them to be great partners as we grow the Company and continue to serve our expanding base of global customers.

“This transaction clearly makes us stronger, and will pay down debt, increase working capital and enable us to approach the longer term with renewed confidence.”

Chief Executive Officer Laurence Anderson said, “With these new partners, we will have greater flexibility to manage through the short-term variations in our business cycle while staying focused on our longer-term growth objectives. We also will have access to additional capital to fund growth initiatives.”

Anderson said that during the transition process, and afterward, “Our customers, partners and suppliers can expect us to continue to build upon our already high level of customer service, driving operational excellence and delivering reliable, essential electricity around the world.”

About APR Energy

APR Energy is the world’s leading provider of fast-track mobile turbine power. Our fast, flexible and full-service power solutions provide customers with rapid access to reliable electricity when and where they need it, for as long as they need it. Combining state-of-the-art, fuel-efficient technology with industry-leading expertise, our scalable turnkey plants help run cities, countries and industries around the world, in both developed and developing markets. For more information, visit the Company’s website at

Press Photo Gallery

Source: APR Energy

Related stocks: LSE:APR OTC-PINK:APRYY

Related Links:

Written by asiafreshnews

January 12, 2016 at 5:04 pm

Posted in Uncategorized

Jubilant Biosys and Sanofi Deutschland GmbH Enter Into a Strategic Alliance Focusing on Metabolic Disorders Therapeutic Area

leave a comment »

BENGALURU /PRNewswire/ —

Collaboration Aimed at Discovery and Development of Small Molecule Inhibitors Through to Phase I Proofof Mechanism in Metabolic Disorders Therapeutic Area

Jubilant Biosys Ltd, a Bengaluru-based subsidiary of Jubilant Life Sciences Ltd, and Sanofi Deutschland GmbH,Frankfurt, Germany, announced a strategic alliance to discover and develop small molecule inhibitors for multiple targets in the metabolic disorders therapeutic area. The research alliance is aimed at developing therapeutic small molecules that will address the unmet needs in diabetes and obesity.


As per the terms of the agreement, Jubilant shall provide Sanofi integrated drug discovery and early development services across computational, synthetic chemistry, biology, GLP/ GMP services, to identify lead candidates and demonstrate clinical proof of mechanism in the metabolic disorders therapeutic areas. The research for the projects, which has been initiated, will be undertaken primarily at state-of-the-art R&D labs of Jubilant Biosys (Bengaluru,India) and Jubilant Chemsys (Noida, India).

Dr. Sriram Rajagopal, Chief Scientific Officer, Jubilant Biosys said: “We are excited to partner with Sanofi, one of the global healthcare leader, to offer our integrated drug discovery solutions. Over the past few years, we have been strengthening our therapeutic area expertise in the scientific perspective and this collaboration is a validation of our efforts. This alliance demonstrates Jubilant’s commitment to global innovation and we look forward to a long mutually beneficial partnership.”

Dr. Philip Just Larsen, Vice President, Global Head of Diabetes Research & Translational Medicine, Sanofi Deutschland GmbH said: “The collaboration with Jubilant underscores our commitment to engaging innovators around the world, as we develop the next generation of improved therapies for people with diabetes.”

About Jubilant Biosys Ltd.:

Jubilant Biosys is a Bengaluru, India based subsidiary of Jubilant Life Sciences Ltd., an integrated global pharmaceutical and life sciences Company headquartered in Noida, India. Jubilant Biosys provides integrated drug discovery solutions to the global pharmaceutical industry. The Company has pioneered the risk shared collaborative discovery research model and demonstrated capabilities over the years through multiple partnerships with global pharmaceuticals firms in the therapeutic areas of oncology, metabolic disorders, pain & inflammation, CNS and others.

For more info: http://jubilantbiosys.com

For Business Development
Dr. Rajiv Tyagi
Tel: +91-80-66628400

Source: Jubilant Biosys Ltd

Written by asiafreshnews

January 12, 2016 at 4:54 pm

Posted in Uncategorized

MediaMath Recognized as “Visionary” in Gartner’s Magic Quadrant for Digital Marketing Hubs

leave a comment »

-Evaluation Based on Completeness of Vision and Ability to Execute

NEW YORK /PRNewswire/ — MediaMath, the global advertising technology provider behind the TerminalOne Marketing Operating System, today announced it has been positioned by Gartner, Inc. in the “Visionaries” quadrant of the “Magic Quadrant for Digital Marketing Hubs.”[i]

“We consider our positioning in the Visionaries Quadrant by Gartner confirmation of our mission to enable advertisers to achieve goal-based marketing at scale,” said Joe Zawadzki, CEO of MediaMath. “Through our open, extensible platform and deep partnerships with other technology providers, we invite marketers around the globe to build a technology stack that helps them achieve the outcomes that matter to their specific business, in a transparent way. We have a number of pending product launches coming in 2016 that we expect to further enhance our market position.”

The Magic Quadrant is a market research report prepared by Gartner analysts that evaluates companies in different industries to provide an overview of a market and its trajectory and maturity. Providers are assessed on their ability to execute and for completeness of vision. The quadrants include “Challengers,” Leaders,” “Niche Players” and “Visionaries.”


Gartner does not endorse any vendor, product or service depicted in its research publications, and does not advise technology users to select only those vendors with the highest ratings or other designation. Gartner research publications consist of the opinions of Gartner’s research organization and should not be construed as statements of fact. Gartner disclaims all warranties, expressed or implied, with respect to this research, including any warranties of merchantability or fitness for a particular purpose.

About MediaMath

MediaMath ( is a global technology company that’s leading the movement to revolutionize traditional marketing and drive transformative results for marketers through its TerminalOne Marketing Operating System™. A pioneer in the industry introducing the first Demand-Side Platform (DSP) with the company’s founding in 2007, MediaMath is the only company of its kind to empower marketers with an extensible, open platform to unleash the power of goal-based marketing at scale, transparently across the enterprise.

Connect with MediaMath

[i] Gartner “Magic Quadrant for Digital Marketing Hubs” by Andrew Frank, Jake Sorofman, Martin Kihn and Christi Eubanks, 5 January, 2016

Media contact:
Ashley Waters
PAN Communications
+1 617-502-4300

Logo –

Source: MediaMath
Related Links:

Written by asiafreshnews

January 12, 2016 at 4:39 pm

Posted in Uncategorized

Janssen to Progress Collaboration with ViiV Healthcare to Develop the First Long Acting Two Drug Injectable Regimen for Treatment of HIV Infection

leave a comment »

CORK, Ireland /PRNewswire/ —

Results from ongoing phase IIb Week 32 study show that if successfully developed and approved, people living with HIV could potentially maintain viral suppression

Janssen Sciences Ireland UC (Janssen), today formalized its collaboration with ViiV Healthcare on phase III development and commercialization of a two drug regimen of two long acting, all-injectable formulations of rilpivirine (a non-nucleoside reverse transcriptase inhibitor by Janssen) and cabotegravir (ViiV Healthcare).

Janssen and ViiV Healthcare have been working together on this regimen, through a number of clinical trial agreements, for several years. Under this new agreement, the phase III development, to evaluate the efficacy, safety and tolerability of the regimen, will be led by ViiV Healthcare with support from Janssen. Each company will manufacture and supply their individual drug formulations following successful phase III completion and regulatory outcomes.

“Despite great progress in developing HIV treatments, the day-to-day burden of managing HIV remains high and poses challenges to ensure people living with HIV maintain an undetectable viral load,” says Paul Stoffels, Chief Scientific Officer, Johnson & Johnson and Worldwide Chairman, Janssen Pharmaceutical Companies. “We are committed to making a real difference for those affected by HIV. The prospect of developing new therapies, such as long acting formulations which are broadly accessible, may offer hope to the many millions affected by HIV around the world.”

At week 32, in an ongoing phase IIb study (LATTE 2, NCT02120352), the investigational long acting, all-injectable combination regimen, given every 4 or 8 weeks, showed comparable efficacy to a daily oral regimen of three HIV medicines (investigational cabotegravir and two nucleoside reverse transcriptase inhibitors (NRTIs)). If successfully developed and approved by regulatory authorities, people living with HIV who are virologically suppressed could be offered an alternative option to the standard oral daily regimen* of three drug therapy.

“While we work toward our long-term goal of developing a preventative HIV vaccine, we are excited to be able to continue to support people living with HIV through innovative improvements,” said Wim Parys, Head of R&D, Global Public Health, Janssen. “Through this collaboration, we have the potential to develop the first long acting, all-injectable two drug regimen as an innovative option for HIV maintenance therapy.”

Since the beginning of the HIV epidemic, almost 75 million people have been infected with the virus. It is estimated that 35 million people are currently living with HIV globally, with 2.5 million people becoming newly infected each year.

*Standard three drug oral therapy contains three active components taken daily: a backbone of two NRTIs, plus either a non-nucleoside reverse transcriptase inhibitor, a protease inhibitor (PI) or an integrase inhibitor (INI).

More information on the Phase IIb LATTE 2 study

LATTE 2 was initiated as a phase IIb, multicentre, open label, 96 week study investigating the safety and efficacy of this first all-injectable long acting combination regimen of rilpivirine and cabotegravir to maintain suppression of viral load. LATTE 2 included adults (n=309) who, after reaching virologic suppression on oral therapy with once-daily investigational oral cabotegravir 30mg + 2 NRTIs (n=286, 93%), were subsequently randomized to one of three study arms to receive either CAB LA + RPV LA injections every 4 weeks (n=115, Q4W), 8 weeks (n=115 Q8W) or continued on oral CAB + NRTIs (n=56).

Viral suppression rates (plasma HIV-1 RNA <50 c/ml by FDA snapshot analysis) for patients at 32 weeks receiving two drug maintenance therapy with investigational long acting cabotegravir (CAB LA) and long acting rilpivirine (RPV LA) whether dosed every 8 weeks (Q8W, 95%) or every 4 weeks (Q4W, 94%) were comparable to the rate observed in patients continuing with a three-drug oral regimen of investigational CAB + NRTIs (91%). Patients switching to CAB LA and RPV LA administered Q4W reported more adverse events (AEs) leading to withdrawal (5%; n=6) compared with those receiving an injection Q8W (2%; n=2) or who continued on oral CAB + NRTIs (2%, n=1). The most common AE reported by patients was injection site pain (93% of injection recipients). Two patients in the Q8W arm (none in the Q4W arm) withdrew due to injection intolerance. Two patients met protocol-defined virologic failure criteria, Q8W (n=1), oral (n=1); neither patient had evidence of resistance at failure.

Results of the LATTE 2 study, co-funded by Janssen and ViiV Healthcare, will be presented at a forthcoming scientific conference.
About EDURANT® (Rilpivirine)

EDURANT® (rilpivirine) is a prescription HIV medicine that is used with other antiretroviral medicines to treat Human Immunodeficiency Virus-1 (HIV-1) in patients:

  • Who have never taken HIV medicines before, and
  • Who have an amount of HIV in their blood (called “viral load”) that is no more than 100,000 copies/mL. Your healthcare professional will measure your viral load

EDURANT® should be taken in combination with other HIV medicines. Your healthcare professional will work with you to find the right combination of HIV medicines

It is important that you remain under the care of your healthcare professional during treatment with EDURANT®

EDURANT® is not recommended for patients less than 12 years of age

EDURANT® does not cure HIV infection or AIDS. You should remain on your HIV medications without stopping to ensure that you control your HIV infection and decrease the risk of HIV-related illnesses. Ask your healthcare professional about how to prevent passing HIV to other people.

Please read Important Safety Information below, and talk to your healthcare professional to learn if EDURANT® is right for you.

Important Safety Information

Can EDURANT® be taken with other medicines?

EDURANT® may affect the way other medicines work and other medicines may affect how EDURANT® works and may cause serious side effects. If you take certain medicines with EDURANT®, the amount of EDURANT® in your body may be too low and it may not work to help control your HIV infection, and the HIV virus in your body may become resistant to EDURANT® or other HIV medicines that are like it. To help get the right amount of medicine in your body, you should always take EDURANT® with a meal. A protein drink alone does not replace a meal.

Do not take EDURANT® if:

  • Your HIV infection has been previously treated with HIV medicines
  • You are taking any of the following medicines:
    • Anti-seizure medicines: carbamazepine (Carbatrol®, Equetro®, Tegretol®, Tegretol-XR®, Teril®, Epitol®), oxcarbazepine (Trileptal®), phenobarbital (Luminal®), phenytoin (Dilantin®, Dilantin-125®, Phenytek®)
    • Anti-tuberculosis (anti-TB) medicines: rifampin (Rifater®, Rifamate®, Rimactane®, Rifadin®), rifapentine (Priftin®)Proton pump inhibitor (PPI) medicine for certain stomach or intestinal problems: esomeprazole (Nexium®, Vimovo®), lansoprazole (Prevacid®), omeprazole (Prilosec®, Zegerid®), pantoprazole sodium (Protonix®), rabeprazole (Aciphex®)
    • More than 1 dose of the steroid medicine dexamethasone or dexamethasone sodium phosphate
    • St. John’s wort (Hypericum perforatum)
  • Especially tell your doctor if you take:
    • Rifabutin (Mycobutin®), a medicine to treat some bacterial infections). Talk to your doctor or pharmacist about the right amount of EDURANT® you should take if you also take rifabutin
    • Medicines used to treat HIV
    • An antacid medicine that contains aluminum, magnesium hydroxide, or calcium carbonate. Take antacids at least 2 hours before or at least 4 hours after you take EDURANT®
    • Medicines to block acid in your stomach, including cimetidine (Tagamet®), famotidine (Pepcid®), nizatidine (Axid®), or ranitidine hydrochloride (Zantac®). Take these medicines at least 12 hours before or at least 4 hours after you take EDURANT®
    • Any of these medicines (if taken by mouth or injection): clarithromycin (Biaxin®), erythromycin (E-Mycin®, Eryc®, Ery-Tab®, PCE®, Pediazole®, Ilosone®), fluconazole (Diflucan®), itraconazole (Sporanox®), ketoconazole (Nizoral®), methadone (Dolophine®), posaconazole (Noxafil®), telithromycin (Ketek®), voriconazole (Vfend®)

This is not a complete list of medicines. Before starting EDURANT®, be sure to tell your healthcare professional about all the medicines you are taking or plan to take, including prescription and nonprescription medicines, vitamins, and herbal supplements.

Before taking EDURANT®, also tell your healthcare professional if you have had or currently have liver problems (including hepatitis B or C), have ever had a mental health problem, are pregnant or planning to become pregnant, or breastfeeding. It is not known if EDURANT® will harm your unborn baby.

You and your healthcare professional will need to decide if taking EDURANT® is right for you.

Do not breastfeed if you are taking EDURANT®. You should not breastfeed if you have HIV because of the chance of passing HIV to your baby

What are the possible side effects of EDURANT®? EDURANT® can cause serious side effects including:

  • Severe skin rash and allergic reactions. Call your doctor right away if you get a rash. Stop taking EDURANT®and seek medical help right away if you get a rash with any of the following symptoms: severe allergic reaction causing swelling of the face, eyes, lips, mouth, tongue, or throat (which may lead to difficulty swallowing or breathing); mouth sores or blisters on your body; inflamed eye (conjunctivitis); fever; dark urine; or pain on the right side of the stomach area (abdominal pain)
  • Depression or mood changes. Tell your doctor right away if you have any of the following symptoms: feeling sad or hopeless, feeling anxious or restless, have thoughts of hurting yourself (suicide), or have tried to hurt yourself
  • Liver problems. People with a history of hepatitis B or C virus infection or who have certain liver function test changes may have an increased risk of developing new or worsening liver problems during treatment. Liver problems were also reported during treatment in some people without a history of liver disease. Your healthcare professional may need to do tests to check liver function before and during treatment
  • Changes in body shape or body fat have been seen in some patients taking HIV medicines. The exact cause and long-term health effects of these conditions are not known
  • Changes in your immune system (immune reconstitution syndrome).
  • Your immune system may get stronger and begin to fight infections. Tell your healthcare professional right away if you start having any new symptoms of infection
  • Other common side effects of EDURANT® include depression, headache, trouble sleeping (insomnia), and rash.

This is not a complete list of all side effects. If you experience these or other symptoms, contact your healthcare professional right away. Do not stop taking EDURANT® or any other medications without first talking to your healthcare professional.

You are encouraged to report side effects of prescription drugs to the FDA. Visit, or call 1-800-FDA-1088. You may also report side effects to Janssen Products, LP at 1-800-JANSSEN (1-800-526-7736).

Please see full product information for more detail.

About cabotegravir

Cabotegravir is an investigational integrase strand transfer inhibitor (INSTI) and analogue of dolutegravir (Tivicay®). Cabotegravir is being developed by ViiV Healthcare for the treatment and prevention of HIV and is currently being evaluated as a once-daily oral tablet formulation and as a long-acting nanosuspension formulation for intramuscular (IM) injection.

About the Janssen Pharmaceutical Companies of Johnson & Johnson

Janssen Sciences Ireland UC is one of the Janssen Pharmaceutical Companies of Johnson & Johnson. At Janssen, we are dedicated to addressing and solving some of the most important unmet medical needs of our time in infectious diseases and vaccines, oncology, immunology, neuroscience, and cardiovascular and metabolic diseases. Driven by our commitment to patients, we develop innovative products, services and healthcare solutions to help people throughout the world.

Cautions Concerning Forward-Looking Statements

This press release contains “forward-looking statements” as defined in the Private Securities Litigation Reform Act of 1995 regarding a new collaboration and product development. The reader is cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of Janssen Sciences Ireland UC and Johnson & Johnson. Risks and uncertainties include, but are not limited to: the potential that the expected benefits and opportunities related to the collaboration may not be realized or may take longer to realize than expected; challenges and uncertainties inherent in new product development, including uncertainty of clinical success and obtaining regulatory approvals; competition, including technological advances, new products and patents attained by competitors; challenges to patents; changes to applicable laws and regulations, including global health care reforms; and trends toward health care cost containment. A further list and description of these risks, uncertainties and other factors can be found in Johnson & Johnson’s Annual Report on Form 10-K for the fiscal year ended December 28, 2014, including in Exhibit 99 thereto, and the company’s subsequent filings with the Securities and Exchange Commission. Copies of these filings are available online at, or on request from Johnson & Johnson. None of the Janssen Pharmaceutical Companies or Johnson & Johnson undertakes to update any forward-looking statement as a result of new information or future events or developments.

Press Contacts:

Daniel De Schryver

Ronan Collins

Investor Contacts:
Louise Mehrotra
Lesley Fishman


Source: Janssen Sciences Ireland

Written by asiafreshnews

January 12, 2016 at 4:29 pm

Posted in Uncategorized